GlassScriptPhysician profile
Jaymon B Patel
NPI 1386084044
$42,100.16
in general payments reported to CMS, 2019-2025
25 companies · $20K in 2025
The $20K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $248 · 2021: $757 · 2022: $817 · 2023: $607 · 2024: $20K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Travel and Lodging: $9,456 · Food and Beverage: $3,488 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,875.00 |
| Travel and Lodging | $9,455.80 |
| Food and Beverage | $3,487.54 |
| Education | $151.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $37,535.32 | 2024-2025 | Voquezna |
| Abbvie INC. | $1,860.85 | 2019-2025 | |
| Janssen Biotech, INC. | $509.04 | 2020-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $453.89 | 2020-2025 | Entyvio |
| Janssen Scientific Affairs, LLC | $372.40 | 2024-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $332.44 | 2020-2025 | Xifaxan |
| Gilead Sciences, INC. | $175.64 | 2020-2025 | |
| Celgene Corporation | $150.75 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $122.96 | 2019-2025 | |
| Lilly USA, LLC | $100.71 | 2024-2025 | Omvoh |
| Pfizer INC. | $89.82 | 2024-2025 | |
| Redhill Biopharma INC. | $76.20 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.74 | 2019 | |
| Merck Sharp & Dohme LLC | $50.67 | 2021-2022 | |
| Madrigal Pharmaceuticals | $46.05 | 2025 | Rezdiffra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $25.46 | 2024 | |
| Daiichi Sankyo INC. | $23.77 | 2024 | Injectafer |
| Nestle Healthcare Nutrition INC. | $23.23 | 2021 | |
| Ardelyx, INC. | $14.91 | 2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $13.70 | 2024 | Dupixent |
| Medtronic, INC. | $13.15 | 2024 | Nexpowder |
| Alfasigma USA, INC. | $12.00 | 2020 | |
| Micro-Tech Endoscopy USA, INC. | $11.98 | 2024 | Cold Snares |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,496.76 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaymon Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.